<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02220660</url>
  </required_header>
  <id_info>
    <org_study_id>1256.2</org_study_id>
    <nct_id>NCT02220660</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers</brief_title>
  <official_title>A Single-blind, Randomised, Two-way Crossover Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study was to compare the systemic exposure of BI 1744 BS and CD&#xD;
      1857 XX (the active metabolite of the pro-drug BI 54903 XX) at steady state following&#xD;
      inhalation of the fixed dose combination (FDC) BI 1744 CL plus BI 54903 XX (as ethanolic&#xD;
      solution for inhalation, EIS) with the systemic exposure following inhalation of the free&#xD;
      dose combination of BI 1744 CL (as aqueous solution for inhalation, AIS) and BI 54903 XX&#xD;
      (EIS), respectively, when administered once-daily via Respimat® Inhaler (Respimat® A for AIS&#xD;
      and Respimat® B for EIS) for 14 days in healthy volunteers. Secondary objectives were: to&#xD;
      compare exposure to BI 1744 BS and CD 1857 XX after a single dose of the BI 1744 CL/BI 54903&#xD;
      XX FDC and the free dose combination, respectively; to compare exposure to BI 54903 XX after&#xD;
      a single dose and at steady state after multiple doses of the BI 1744 CL/BI 54903 XX fixed&#xD;
      dose combination and the free dose combination, respectively; to compare the safety and&#xD;
      tolerability of BI 1744 CL and BI 54903 XX when administered as BI 1744 CL/BI 54903 XX fixed&#xD;
      dose combination and as the free dose combination, respectively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t,ss (area under the concentration time curve of the analyte in plasma from 0 to time t at steady state)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-t,ss (area under the concentration time curve of the analyte in plasma from 0 to time t at steady state)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cpre (pre-dose concentration of the analyte in plasma)</measure>
    <time_frame>immediately before drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt1-t2 (area under the concentration time curve of the analyte in plasma over the time interval t1 to t2)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t (area under the concentration time curve of the analyte in plasma from 0 to time t)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ (area under the plasma concentration-time curve over a uniform dosing interval τ)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUCtz-∞(the percentage of the AUC0-∞that is obtained by extrapolation)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to the maximum concentration of the analyte in plasma)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz (terminal rate constant of the analyte in plasma)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½ (terminal half-life of the analyte in plasma)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTih (mean residence time of the analyte in the body after inhaled administration)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (apparent clearance of the analyte in the plasma after extravascular administration)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution of the analyte during the terminal phase following an extravascular dose)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Free dose combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed dose combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1744 CL</intervention_name>
    <arm_group_label>Free dose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 54903 XX</intervention_name>
    <arm_group_label>Free dose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1744 CL + BI 54903 XX FDC</intervention_name>
    <arm_group_label>Fixed dose combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Fixed dose combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males and females according to the following criteria: Based upon a complete&#xD;
             medical history, including the physical examination, vital signs (Blood pressure (BP),&#xD;
             Pulse rate (PR)), 12-lead Electrocardiogram (ECG), clinical laboratory tests&#xD;
&#xD;
          -  Age &gt;= 21 and &lt;= 50 years&#xD;
&#xD;
          -  BMI &gt;= 18.5 and &lt;= 29.9 kg/m2&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with Good Clinical Practice (GCP) and the local legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any finding of the medical examination (including BP, PR and ECG) deviating from&#xD;
             normal and of clinical relevance&#xD;
&#xD;
          -  Any evidence of a clinically relevant concomitant disease&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          -  Surgery of the gastrointestinal tract (except appendectomy)&#xD;
&#xD;
          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or&#xD;
             neurological disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells or blackouts&#xD;
&#xD;
          -  Chronic or relevant acute infections&#xD;
&#xD;
          -  History of relevant allergy/hypersensitivity (including allergy to drug or its&#xD;
             excipients)&#xD;
&#xD;
          -  Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less&#xD;
             than 10 half-lives of the respective drug prior to administration or during the trial&#xD;
&#xD;
          -  Use of drugs which might reasonably influence the results of the trial based on the&#xD;
             knowledge at the time of protocol preparation within 10 days prior to administration&#xD;
             or during the trial&#xD;
&#xD;
          -  Participation in another trial with an investigational drug within two months prior to&#xD;
             administration or during the trial&#xD;
&#xD;
          -  Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)&#xD;
&#xD;
          -  Inability to refrain from smoking on trial days&#xD;
&#xD;
          -  alcohol abuse (more than 40 g/day)&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Blood donation (&gt; 100 mL within four weeks prior to administration or during the&#xD;
             trial)&#xD;
&#xD;
          -  Excessive physical activities (within one week prior to administration or during the&#xD;
             trial)&#xD;
&#xD;
          -  Any laboratory value outside the reference range that is of clinical relevance&#xD;
&#xD;
          -  Inability to comply with dietary regimen of trial site&#xD;
&#xD;
        For female Subjects:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  No adequate contraception (adequate contraception e.g. sterilization, intrauterine&#xD;
             pessary (IUP), oral contraceptives)&#xD;
&#xD;
          -  Inability to maintain this adequate contraception during the whole study period&#xD;
&#xD;
          -  Lactation period&#xD;
&#xD;
        Exclusion criteria specific for this study due to the known class side effect profile of&#xD;
        ß2-mimetics and inhaled corticosteroids:&#xD;
&#xD;
          -  Asthma or history of pulmonary hyperreactivity&#xD;
&#xD;
          -  Hyperthyreosis&#xD;
&#xD;
          -  Allergic rhinitis in need of treatment&#xD;
&#xD;
          -  Clinically relevant cardiac arrhythmia&#xD;
&#xD;
          -  Bacterial and viral infections of the lung including tuberculosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>August 19, 2014</study_first_submitted>
  <study_first_submitted_qc>August 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2014</study_first_posted>
  <last_update_submitted>August 19, 2014</last_update_submitted>
  <last_update_submitted_qc>August 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02220660
org study id: 1256.2
nct id: NCT02220660
lead sponsor: 
The primary objective of this study was to compare the systemic exposure of BI 1744 BS and CD
      1857 XX (the active metabolite of the pro-drug BI 54903 XX) at steady state following
      inhalation of the fixed dose combination (FDC) BI 1744 CL plus BI 54903 XX (as ethanolic
      solution for inhalation, EIS) with the systemic exposure following inhalation of the free
      dose combination of BI 1744 CL (as aqueous solution for inhalation, AIS) and BI 54903 XX
      (EIS), respectively, when administered once-daily via Respimat® Inhaler (Respimat® A for AIS
      and Respimat® B for EIS) for 14 days in healthy volunteers. Secondary objectives were: to
      compare exposure to BI 1744 BS and CD 1857 XX after a single dose of the BI 1744 CL/BI 54903
      XX FDC and the free dose combination, respectively; to compare exposure to BI 54903 XX after
      a single dose and at steady state after multiple doses of the BI 1744 CL/BI 54903 XX fixed
      dose combination and the free dose combination, respectively; to compare the safety and
      tolerability of BI 1744 CL and BI 54903 XX when administered as BI 1744 CL/BI 54903 XX fixed
      dose combination and as the free dose combination, respectively.
allocation: Randomized
intervention model: Crossover Assignment
primary purpose: Treatment
masking: Single
measure: AUC0-t,ss (area under the concentration time curve of the analyte in plasma from 0 to time t at steady state)
time frame: up to 24 hours after drug administration
measure: Cmax (maximum measured concentration of the analyte in plasma)
time frame: up to 24 hours after drug administration
measure: AUC0-t,ss (area under the concentration time curve of the analyte in plasma from 0 to time t at steady state)
time frame: up to 24 hours after drug administration
measure: Cpre (pre-dose concentration of the analyte in plasma)
time frame: immediately before drug administration
measure: AUCt1-t2 (area under the concentration time curve of the analyte in plasma over the time interval t1 to t2)
time frame: up to 24 hours after drug administration
measure: AUC0-t (area under the concentration time curve of the analyte in plasma from 0 to time t)
time frame: up to 24 hours after drug administration
measure: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)
time frame: up to 24 hours after drug administration
measure: AUCτ (area under the plasma concentration-time curve over a uniform dosing interval τ)
time frame: up to 24 hours after drug administration
measure: AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
time frame: up to 24 hours after drug administration
measure: %AUCtz-∞(the percentage of the AUC0-∞that is obtained by extrapolation)
time frame: up to 24 hours after drug administration
measure: tmax (time from dosing to the maximum concentration of the analyte in plasma)
time frame: up to 24 hours after drug administration
measure: λz (terminal rate constant of the analyte in plasma)
time frame: up to 24 hours after drug administration
measure: t½ (terminal half-life of the analyte in plasma)
time frame: up to 24 hours after drug administration
measure: MRTih (mean residence time of the analyte in the body after inhaled administration)
time frame: up to 24 hours after drug administration
measure: CL/F (apparent clearance of the analyte in the plasma after extravascular administration)
time frame: up to 24 hours after drug administration
measure: Vz/F (apparent volume of distribution of the analyte during the terminal phase following an extravascular dose)
time frame: up to 24 hours after drug administration
arm group label: Free dose combination
arm group type: Active Comparator
arm group label: Fixed dose combination
arm group type: Experimental
intervention type: Drug
intervention name: BI 1744 CL
arm group label: Free dose combination
intervention type: Drug
intervention name: BI 54903 XX
arm group label: Free dose combination
intervention type: Drug
intervention name: BI 1744 CL + BI 54903 XX FDC
arm group label: Fixed dose combination
intervention type: Drug
intervention name: Placebo
arm group label: Fixed dose combination
criteria: 
gender: All
minimum age: 21 Years
maximum age: 50 Years
healthy volunteers: Accepts Healthy Volunteers
url: http://trials.boehringer-ingelheim.com
description: Related Info
responsible party type: Sponsor
mesh term: Olodaterol